Document:

Amended and Restated Executive Change in Control Severance Benefits Agreement

 Exhibit 10.2 

AMENDED AND RESTATED EXECUTIVE 

CHANGE IN CONTROL 

SEVERANCE BENEFITS AGREEMENT 

THIS AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITS AGREEMENT (the “AGREEMENT”) is entered
into on May 4, 2010, between David B. Bell (“EXECUTIVE”) and INTERSIL CORPORATION, a Delaware corporation (the “COMPANY”). 

WHEREAS, this Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence
of specific events after the date hereof. 
 NOW THEREFORE, the Company and Executive hereby agree as follows:

 Certain capitalized terms used in this Agreement are defined in Article VI. 

ARTICLE I 

EMPLOYMENT BY THE COMPANY 

1.1 Executive is currently employed as an executive of the Company. 

1.2 The Company and Executive wish to set forth the compensation and benefits which Executive shall be entitled to receive if
Executive’s employment with the Company terminates following a Change in Control under the circumstances described in Article II of this Agreement. 

1.3 The duties and obligations of the Company to Executive under this Agreement shall be in consideration for Executive’s
continued employment with the Company and, in the event a Covered Termination occurs, Executive’s execution of the general waiver and release described in Section 3.2. 

ARTICLE II 

SEVERANCE BENEFIT 

2.1 Entitlement to Severance Benefits. If Executive’s employment terminates due to an Involuntary Termination or a Voluntary
Termination for Good Reason, in either case, within twelve (12) months following the effective date of a Change in Control, the termination of employment will be a Covered Termination and the Company shall pay Executive the compensation and
benefits described in this Agreement. If Executive’s employment terminates, but not due to an Involuntary Termination or a Voluntary Termination for Good Reason, in any case, within twelve (12) months following the effective date of a
Change in Control, then the termination of employment will not be a Covered Termination and Executive will not be entitled to receive any payments or benefits under this Agreement. 

Payment of any benefits described in this Article II shall be subject to the restrictions and limitations set forth in Article III of
this Agreement. 
 DAVID BELL CIC SEVERANCE AGREEMENT 

 2.2 Severance Payments. In the event of a Covered Termination, the Company shall
continue to pay the Executive’s Annual Base Pay for two (2) years (the “Severance Period”). In addition, the Company shall make four payments, each in the amount of fifty-five percent (55%) of the Executive’s
Annual Base Pay, payable within 30 days after each of the first two March 1 and September 1 dates following such Covered Termination. All payments made pursuant to this Section 2.2 shall be made less applicable deductions and
withholdings and are payable in accordance with Intersil’s normal payroll practices immediately prior to the Covered Termination. 

2.3 Welfare Benefits. Following a Covered Termination, Executive and his covered dependents will be eligible to convert his
and his covered dependents’ life insurance coverage to individual policies and the Company shall reimburse the Executive for the applicable premium(s) during the Severance Period. Following a Covered Termination, either (x) Executive and
his spouse will, if eligible, be covered in the retiree medical plan maintained by the Company (the “Retiree Medical Plan”) or (y) if not so eligible, the Executive will be reimbursed for his and his covered dependents’
applicable premium(s) during the Severance Period for continuation coverage under the Company’s health insurance plans. If the Executive qualifies to participate in the Retiree Medical Plan, upon his Covered Termination, the Executive and his
spouse will be eligible to participate in the Retiree Medical Plan and the Company will make the full payment of the premiums for coverage of the Executive and his spouse under the Retiree Medical Plan; provided, however, that if the Retiree Medical
Plan is terminated with respect to all other employees of Intersil after his termination of employment hereunder, the Executive shall no longer be provided coverage under the Retiree Medical Plan; and provided, further, however, that the Company
shall cease paying his or his spouse’s premiums under the Retiree Medical Plan when the Executive or his spouse, as the case may be, becomes eligible for Medicare or becomes covered under another employer’s medical plan. The Executive
agrees to immediately notify the Company if he or his spouse becomes eligible for Medicare or covered by another employer’s medical plan. The Executive will not be reimbursed for the income, employment or other taxes payable due to any of the
benefits provided to Executive, his spouse or any of his covered dependents under this Section 2.3. Any reimbursement or payment of premiums or other costs by the Company pursuant to this Section shall be made no later than the end of the
calendar year following the calendar year in which the applicable premium or other cost is incurred by the Executive 

2.4 Timing of Payments. Any payments scheduled to be provided pursuant to this Section 2 prior to the 45
th day following a Covered Termination shall instead be
paid in a lump sum on the 45th day following such
termination and all payments scheduled to be made thereafter shall be made as regularly scheduled. 
 2.5 Mitigation.
Except as otherwise specifically provided herein, Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment
provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or by retirement benefits after the date of the Covered Termination, or otherwise. 

 

					
	Intersil Confidential	  		  	

 ARTICLE III 

LIMITATIONS AND CONDITIONS ON BENEFITS 

3.1 Withholding of Taxes. The Company shall withhold appropriate federal, state or local income and employment taxes from any
payments hereunder. 
 3.2 Employee Agreement and Release Prior to receipt of Benefits. Upon the occurrence of a Covered
Termination, and prior to the receipt of any benefits under this Agreement on account of the occurrence of a Covered Termination, Executive shall, as of the date of a Covered Termination, execute an employee agreement and release in the form
attached hereto as Exhibit A; provided that such agreement and release have become binding and effective in accordance with the terms thereof on or before the forty-fifth (45th) day following the date of the Executive’s termination
of employment. Such employee agreement and release shall specifically relate to all of Executive’s rights and claims in existence at the time of such execution and shall confirm Executive’s obligations under the Company’s standard
form of proprietary information agreement. It is understood that such employee release and agreement shall comply with applicable law. In the event that Executive does not execute such release and agreement such that it is binding and effective (and
all applicable revocation periods have expired) within forty five (45) days following such termination, no benefits shall be payable under this Agreement and this Agreement shall be null and void. 

3.3. Code Section 409A. Notwithstanding any other provision of this Agreement to the contrary, if
Executive is a “specified employee” within the meaning of Code Section 409A and the regulations issued thereunder, and a payment or benefit provided for in this Agreement would be subject to additional tax under Code Section 409A
if such payment or benefit is paid within six months after Executive’s “separation from service” (within the meaning of Code Section 409A), then such payment or benefit required under this Agreement shall not be paid (or
commence) during the six-month period immediately following Executive’s separation from service except as provided in the immediately following sentence. In such an event, any payments or benefits that would otherwise have been made or provided
during such six-month period and which would have incurred such additional tax under Code Section 409A shall instead be paid to Executive (with simple interest calculated thereon at LIBOR plus 50 basis points as of the date of such separation
from service) in a lump-sum payment on the earlier of (i) the first business day of the seventh month following Executive’s separation from service or (ii) the
10th business day following Executive’s death. If
Executive’s termination of employment hereunder does not constitute a “separation from service” within the meaning of Code Section 409A, then any amounts payable hereunder on account of a termination of Executive’s
employment and which are subject to Code Section 409A shall not be paid until Executive has experienced a “separation from service” within the meaning of Code Section 409A. 

ARTICLE IV 

OTHER RIGHTS AND BENEFITS 

4.1 Non-exclusivity. Nothing in this Agreement shall prevent or limit Executive’s continuing or future participation in any
benefit, bonus, incentive or other plans, programs, policies or practices provided by the Company and for which Executive may otherwise qualify, nor shall anything herein limit or otherwise affect such rights as Executive may have under any

  

					
	Intersil Confidential	  		  	

 
stock option or other agreements with the Company. Except as otherwise expressly provided herein, amounts which are vested benefits or which Executive is otherwise entitled to receive under any
plan, policy, practice or program of the Company at or subsequent to the date of a Covered Termination shall be payable in accordance with such plan, policy, practice or program. 

4.2 Parachute Payments. If all or any portion of the amounts payable or benefits provided to the Executive under this Agreement or
otherwise are ‘excess parachute payments’ and are subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), and if the net after-tax amount (taking into account all applicable taxes payable by the
Executive, including without limitation any Excise Tax) that the Executive would receive with respect to such payments or benefits does not exceed the net after-tax amount the Executive would receive if the amount of such payments and benefits were
reduced to the maximum amount which could otherwise be payable to the Executive without the imposition of the Excise Tax, then, only to the extent necessary to eliminate the imposition of the Excise Tax, such payments and benefits shall be reduced,
in the order and of the type mutually agreed to by the Executive and the Company, provided however, that, to the extent necessary to comply with Section 409A of the Code, such forfeitures shall first apply against the latest scheduled cash
payments, then to current cash payments and then to non-cash benefits. The calculations required under this Section 4.2 shall be prepared by the Company and reviewed for accuracy by the Executive and the Company’s regular certified public
accountants. 
 4.3 Stock Options, Deferred Stock Units and Restricted Stock. In the event of a Covered Termination, all
stock options, deferred stock units, and restricted stock granted to Executive by the Company during the Executive’s employment with the Company then outstanding (i) shall immediately become fully vested (and with respect to the stock
options, fully exercisable), and if any such award is subject to performance criteria, then such award shall fully vest in the amount such award would have vested at the performance level achieved through the last day of the quarter immediately
preceding the date of such Covered Termination (or, if it is not reasonably practicable to measure performance following the Change in Control preceding such Covered Termination (as determined in good faith by the Company), performance shall be
measured through the last day of the quarter immediately preceding such Change in Control), and (ii) Executive shall have (A) twelve (12) months following a Covered Termination (or the remaining term of the applicable option grant if
shorter than 12 months) to exercise any stock options which were converted from Elantec options or awards granted on or after January 1, 2006, and (B) shall have twenty-four (24) months following a Covered Termination (or the
remaining term of the applicable option grant if shorter than 24 months) to exercise any awards not described in 4.3(ii)(A). If applicable, the Company shall only amend all such stock options, deferred stock units or restricted stock grants in a
manner that will not adversely affect Executive’s financial position and that does not subject Executive to liability under Section 16(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 

ARTICLE V 

NON-ALIENATION OF BENEFITS 

No benefit hereunder shall be subject to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge, and any
attempt to so subject a benefit hereunder shall be void. 
  

					
	Intersil Confidential	  		  	

 ARTICLE VI 

DEFINITIONS 

For purposes of the Agreement, the following terms shall have the meanings set forth below: 

6.1 “Agreement” means this Amended and Restated Executive Change in Control Severance Benefits Agreement. 

6.2 “Annual Base Pay” means Executive’s annual base pay at the rate in effect during the last regularly scheduled
payroll period immediately preceding (i) the Change in Control or (ii) the Covered Termination, whichever is greater. 

6.3 “Change in Control” means the consummation of any of the following transactions after the date hereof: 

(a) a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result
in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least fifty percent (50%) of the
total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation; 

(b) a liquidation or dissolution of the Company; 

(c) the sale, lease, exchange or other transfer or disposition by the Company of all or substantially all (more than fifty percent
(50%)) of the Company’s assets; 
 (d) any person (as such term is used in Section 13(d) of the Exchange
Act) becomes the beneficial owner (within the meaning of Rule 13d-3 under the Exchange Act) directly or indirectly of 25% or more of the Company’s outstanding Common Stock other than (x) a trustee or other fiduciary holding securities
under an employee benefit plan of the Company or a Subsidiary, (y) a person who acquires such Common Stock directly from the Company in a privately-negotiated transaction or in an underwritten public offering or (z) a person (as such term
is used in Section 13(d) of the Exchange Act) who is already a beneficial owner (within the meaning of Rule 13d-3 under the Exchange Act) directly or indirectly of 25% or more of the Company’s outstanding Common Stock; or 

(e) a change in the composition of the Board of Directors of the Company such that the individuals who as of any date constitute
the Board of Directors of the Company (the “Incumbent Board”) cease to constitute a majority of the Board of Directors of the Company at any time during the 24-month period immediately following such date; provided, however, that if the
election, or nomination for election by the Company’s shareholders, of any new director was approved by a vote of at least a majority of the Incumbent Board, such new director shall be considered as a member of the Incumbent Board, and provided
further that any reductions in the size of the Board of Directors of the Company that are instituted voluntarily by the Incumbent Board shall not constitute a Change in Control, and after any such reduction the “Incumbent Board” shall mean
the Board of Directors of the Company as so reduced. 
  

					
	Intersil Confidential	  		  	

 Notwithstanding the foregoing, “Incumbent Directors” shall not include an
individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company. 

6.4 “Company” means Intersil Corporation, a Delaware corporation, and any successor thereto. 

6.5 “Covered Termination” means an Involuntary Termination or a Voluntary Termination for Good Reason, in either case,
within twelve (12) months following a Change in Control after the date hereof. No other event shall be a Covered Termination for purposes of this Agreement. 

6.6 “Involuntary Termination” means Executive’s dismissal or discharge by the Company or its subsidiaries (or, if
applicable, by the successor entity) for reasons other than fraud, misappropriation or embezzlement on the part of Executive which resulted in material loss, damage or injury to the Company. Notwithstanding the foregoing, Executive shall not be
deemed to have been terminated for one of these reasons unless and until there shall have been delivered to Executive a copy of a resolution, duly adopted by the affirmative vote of not less than three-quarters of the entire membership of the
Company’s Board of Directors at a meeting of the Company’s Board of Directors called and held for such purpose (after reasonable notice to Executive and an opportunity for the Executive, together with Executive’s counsel, to be heard
before the Company’s Board of Directors), finding that in the good faith opinion of the Company’s Board of Directors, Executive was guilty of conduct set forth in the immediately preceding sentence and specifying the particulars thereof in
detail. 
 The termination of the Executive’s employment would not be deemed to be an “Involuntary Termination”
if such termination occurs as a result of the death or Disability (as defined in Executive’s employment agreement with the Company) of Executive. 

6.7 “Voluntary Termination for Good Reason” means that the Executive voluntarily terminates his employment after any of
the following are undertaken without Executive’s express written consent: 
 (a) the assignment to Executive of any
duties or responsibilities which result in any diminution or adverse change of Executive’s position, status or circumstances of employment as in effect immediately prior to the Change in Control of the Company; any removal of Executive from or
any failure to reelect Executive to any of such positions, except in connection with the termination of his employment for death, Disability or retirement or such termination by the Company other than an Involuntary Termination; 

(b) a reduction by the Company in Executive’s Annual Base Pay or targeted annual cash incentive bonus in effect at the time;

 (c) any failure by the Company to continue in effect any benefit plan or arrangement, including incentive plans or
plans to receive securities of the Company, in which Executive is participating at the time of the Change in Control of the Company (hereinafter referred to as “Benefit Plans”), or the taking of any action by the Company which would
adversely affect Executive’s participation in or reduce Executive’s benefits under any Benefit 
  

					
	Intersil Confidential	  		  	

 
Plans or deprive Executive of any fringe benefit enjoyed by Executive at the time of the Change in Control of the Company, provided, however, that such termination shall not be deemed to be a
“Voluntary Termination for Good Reason” if the Company offers a range of benefit plans and programs which, taken as a whole, are comparable to the Benefit Plans, as determined in good faith by Executive; 

(d) a relocation of Executive, or the Company’s principal executive offices if Executive’s principal office is at such
offices, to a location more than fifteen (15) miles from the location at which Executive performed Executive’s duties immediately prior to the Change in Control of the Company, except for required travel by Executive on the Company’s
business to an extent substantially consistent with Executive’s business travel obligations at the time of the Change in Control of the Company; 

(e) any breach by the Company of any provision of this Agreement; or 

(f) any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company. 

ARTICLE VII 

GENERAL PROVISIONS 

7.1 Employment Status. This Agreement does not constitute a contract of employment or impose on Executive any obligation to remain
as an employee, or impose on the Company any obligation (i) to retain Executive as an employee, (ii) to change the status of Executive as an at-will employee, if applicable or (iii) to change the Company’s policies regarding
termination of employment. 
 7.2 Notices. Any notices provided hereunder must be in writing and such notices or any
other written communication shall be deemed effective upon the earlier of personal delivery (including personal delivery by telex or facsimile) or the third day after mailing by first class mail, to the Company at its primary office location and to
Executive at his address as listed in the Company’s payroll records. Any payments made by the Company to Executive under the terms of this Agreement shall be delivered to Executive either in person or at his address as listed in the
Company’s payroll records. 
 7.3 Severability. Whenever possible, each provision of this Agreement will be
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such
invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had
never been contained herein. 
 7.4 Waiver. If either party should waive any breach of any provisions of the Agreement,
he or it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 
  

					
	Intersil Confidential	  		  	

 7.5 Complete Agreement. This Agreement, including Exhibit A and other written
agreements referred to in this Agreement, constitutes the entire agreement between Executive and the Company and it is the complete, final, and exclusive embodiment of their agreement with regard to the subject matter hereof, and expressly
supersedes all other agreements, promises or understandings, whether oral or written, including, without limitation, Executive’s prior Executive Change in Control Severance Benefits Agreement entered into on April 2, 2007. For avoidance of
doubt, the parties hereto acknowledge and agree that in the event of any termination of Executive’s employment with the Company which constitutes a Covered Termination hereunder, Executive shall be entitled to the rights and benefits provided
for in this Agreement in lieu of any rights or benefits provided for in his employment agreement with the Company. This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein.

 7.6 Amendment or Termination of Agreement. This Agreement may be changed or terminated only upon the mutual written
consent of the Company and Executive. The written consent of the Company to a change or termination of this Agreement must be signed by an executive officer of the Company after such change or termination has been approved by the Compensation
Committee of the Company’s Board of Directors. 
 7.7 Counterparts. This Agreement may be executed in separate
counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. 

7.8 Headings. The headings of the Articles and sections hereof are inserted for convenience only and shall not be deemed to
constitute a part hereof nor to affect the meaning thereof. 
 7.9 Successors and Assigns. This Agreement is intended to
bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of his duties hereunder and Executive may not
assign any of his rights hereunder without the written consent of the Company, which consent shall not be withheld unreasonably. 

7.10 Attorneys’ Fees. If Executive brings any action to enforce his rights hereunder, Executive shall be entitled to recover
his reasonable attorneys’ fees and costs incurred in connection with such action if Executive is the prevailing party in such action. Any reimbursements made by the Company to the Executive pursuant to this Section shall be made no later than
the end of the calendar year following the calendar year in which the related cost is incurred by the Executive. 
 7.11
Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of California without reference to conflict of laws provisions thereof. 

7.12 Non-Publication. The parties mutually agree not to disclose publicly the terms of this Agreement except to the extent that
disclosure is mandated by applicable law. 
  

					
	Intersil Confidential	  		  	

 7.13 Construction of Agreement. In the event of a conflict between the text of this
Agreement and any summary, description or other information regarding this Agreement, the text of this Agreement shall control. 

[Signatures Appear on the Following Page] 
  

					
	Intersil Confidential	  		  	

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year written above.

  

							
	 INTERSIL CORPORATION

a Delaware Corporation
	 		 	EXECUTIVE
			
	 /s/ Vern Kelley
	 		 	 /s/ David B. Bell

		 		 	Name:	 	David B. Bell
		 		 	Title:	 	President and Chief Executive Officer
			
		 		 	 May 25, 2010

		 		 	Date

  

					
	Intersil Confidential	  		  	

 Exhibit A 

Intersil Corporation 

Employee Release Agreement 

Except as otherwise set forth in this Employee Release Agreement (the “Agreement”), I, David B. Bell, hereby release, acquit
and forever discharge Intersil Corporation (the “Company”), its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims,
liabilities, demands, causes of action, costs, expenses, attorneys’ fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed
(other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and
including the date I sign this Agreement, including but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including
but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests
in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights
Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”); the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract
law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company
from its obligation to indemnify me pursuant to the Company’s Indemnification Agreement and to provide me with continued coverage under the Company’s directors and officers liability insurance policy to the same extent that it has provided
such coverage to previously departed officers and directors of the Company. 
 I acknowledge that I have read and understand
Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him or
her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any
claims I may have against the Company or any other related party identified above. Accordingly, I agree and acknowledge that the above general release provision applies not only to claims that are presently known, suspected, or disclosed to me, but
also to claims that are presently unknown, unsuspected, or undisclosed to me. I acknowledge that I am assuming the risk that the facts may turn out to be different from what I believe them to be and agree that the general release in this Agreement
shall be in all respects effective and not subject to termination or rescission because of such mistaken belief. 
  

					
	Intersil Confidential	  		  	

 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may
have under the ADEA. I also acknowledge that the consideration given for the waiver and release in the preceding paragraph hereof is in addition to anything of value which I was already entitled. I further acknowledge that I have been advised by
this writing, as required by the ADEA, that: (a) my waiver and release do not apply to any rights or claims that may arise after the date I sign this Agreement; (b) I have the right to consult with an attorney prior to executing this
Agreement; (c) I have twenty-one (21) days to consider this Agreement (although I may choose to voluntarily execute this Agreement earlier); (d) I have seven (7) days following my execution of this Agreement to revoke the
Agreement by providing written notice to the Company; and (e) this Agreement shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day after this Agreement is executed by me, provided that
the Company has also executed this Agreement by that date. 
  

									
	DAVID B. BELL	 		 	INTERSIL CORPORATION
				
	  
	 		 	By:	 	  

					
	Dated:	 	  
	 		 	Title:	 	  

					
		 		 		 	Dated:	 	  

  

					
	Intersil ConfidentialAdditional Sponsored Research Agreement

 EXHIBIT 10.7 

ADDITIONAL SPONSORED RESEARCH AGREEMENT 

This agreement (this “Agreement”) is made effective as of the 24th day of February 2009 (the “Effective Date”)
between: 
 UNIVERSITY HEALTH NETWORK an Ontario corporation incorporated by special statute under the University
Health Network Act, 1997, having a principal office at 190 Elizabeth Street, R. Fraser Elliott Building - Room 1S-417, Toronto, Ontario, M5G 2C4, Facsimile (416) 977-4765 

(“UHN”) 

-AND- 
 MED
BIOGENE INC., a British Columbia corporation, having a principal office at 300 - 2386 East Mall, Gerald McGavin Building, Vancouver, British Columbia, V6T 1Z3, Facsimile (604) 827-5120 

(“MBI”; herein UHN and MBI may be referred to individually as a “Party”, or collectively as the
“Parties”.) 
 Whereas: 

MBI and UHN are parties to an exclusive license agreement (the “Exclusive License Agreement”) dated effective
April 14th, 2008 as amended the even date herewith
for certain technology owned by UHN and developed by UHN researchers Drs. Ming-Sound Tsao and Frances A. Shepherd (collectively, the “Principal Investigators”) relating to 3-gene and 6-gene prognostic messenger RNA
(“mRNA”) expression-based signatures for prognosing early-stage non-small-cell lung cancer survival (the “Licensed Technology”) and a sponsored research agreement (the “Sponsored Research
Agreement”) dated effective April 14th, 2008
as amended the even date herewith for a research program (the “Research Program”) relating to the Licensed Technology. 

Pursuant to an additional exclusive license agreement (the “Additional Exclusive License Agreement”) between the Parties dated the even
date herewith, UHN grants to MBI an exclusive license to further develop and commercialize certain additional technology owned by UHN and developed by the Principal Investigators relating to a 15-gene prognostic mRNA expression-based signature to be
used in the clinical management of lung cancers as more specifically described therein (the “Additional Licensed Technology”). 

UHN desires to undertake under the direction of the Principal Investigators, and MBI desires to financially support, a research program
(the “Additional Research Program”) relating to a 15-gene prognostic mRNA expression-based signature to be used in the clinical management of lung cancers, namely the further research, development and validation of the
Additional Licensed Technology in respect of said prognostic mRNA expression-based signature as more fully outlined in Schedule A attached hereto and in a manner compatible with UHN’s role as a world-class health care research and teaching
institution. 
 As provided for in the Additional Exclusive License Agreement, UHN grants to MBI an exclusive license to further develop and
commercialize the technology developed in the Additional Research Program. 
 NOW THEREFORE THIS AGREEMENT WITNESSES that in
consideration for the mutual promises, representations, covenants and agreements of the Parties contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as
follows. 

 ARTICLE 1 - SCOPE OF WORK 

1.1 Additional Research Program. UHN, under the direction of the Principal Investigators, will undertake the Additional Research Program in
accordance with the procedures, specifications and timelines described out in Schedule A attached hereto and this Agreement. The Parties acknowledge that the Additional Research Program will be carried out in vitro utilizing human biological
material and that no in vivo studies will be undertaken. UHN shall ensure that its employees who perform UHN’s obligations under the Additional Research Program are appropriately trained and qualified to perform the obligations in
accordance with the terms of this Agreement. 
 1.2 Principal Investigators. The Additional Research Program will be conducted under the
direction of the Principal Investigators. UHN shall ensure that the Principal Investigators are available to perform the Additional Research Program and shall not replace such persons with any other person without the prior written approval of MBI.
In the event of the death, incapacity or total disability of one or both of the Principal Investigators or one or both of the Principal Investigators ceases employment or terminates his/her association with UHN, UHN shall notify MBI in writing and
may nominate one or more replacements. If no nominee satisfactory to MBI is found, MBI may immediately terminate this Agreement under Section 9.3. 

1.3 UHN Research Ethics Board Approval. UHN represents and warrants that it has received, or will receive, all applicable approvals of the UHN
Research Ethics Board operating under the Tri-Council Policy Statement, “Ethical Conduct for Research Involving Humans”, 1998 (the “UHN REB”), as amended from time to time, in respect of undertaking the Additional Research
Program and the use of human biological material in respect thereto. 
 1.4 Subcontractors. 

 

	(a)	Any subcontractor used by UHN to perform the Additional Research Program or any other obligations hereunder shall be subject to written obligations that comply with the
requirements set out herein for the performance of the Additional Research Program and provide for the ownership and allocation of Intellectual Property rights and data and the confidentiality of information, record-keeping and access that are
consistent with the intent and terms of this Agreement. UHN shall make copies of each subcontractor agreement available to MBI. 

  

	(b)	UHN shall remain liable for the performance of any of its obligations delegated to a subcontractor. Any breach by UHN’s subcontractors shall be deemed a breach by
UHN, and MBI may proceed directly against UHN for such breach without any obligation to first proceed against such subcontractors. 

1.5 Delays. UHN shall promptly notify MBI of any factor, occurrence or event that is likely to occasion its delay or failure to perform its
obligations under the Additional Research Program in accordance with the timelines therefor. In such event, the Parties shall cooperate to expedite the performance of the Additional Research Program. 

ARTICLE 2 - FINANCIAL SUPPORT AND ADDITIONAL 

RESEARCH PROGRAM SUCCESS FEES 

2.1 Financial Support. Subject to suspension under Section 9.6, MBI shall provide to UHN financial support to conduct the Additional Research
Program in the aggregate amount of $[*] (inclusive of [*]% institutional overhead) (the “MBI Grant”), as more fully outlined in Schedule B attached hereto. MBI shall make such payments in advance of each relevant Phase of the
Additional Research Program commencing on the Effective Date, as set out in Schedule B, subject to receipt by MBI of any outstanding reports to be provided by the Principal Investigators under Section 4.2 below. 

2.2 Application of Funds. UHN hereby agrees that it shall apply the MBI Grant solely in payment of the Principal Investigators’ costs and
expenses in performing the Additional Research Program in accordance with this Agreement. UHN shall apply the funds paid to it in respect of the MBI Grant in accordance with UHN’s internal policies and procedures. 

 

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 2 

 2.3 Funds Held in Trust. UHN hereby agrees that all funds paid to it by MBI in respect of MBI Grant
shall be deemed to be held in trust by UHN for the benefit of MBI until applied by UHN to the Principal Investigators’ costs and expenses in accordance with this Article 2. All funds deemed to be held in trust hereunder shall be deemed to be
held separate from and form no part of UHN’s money, assets or revenues, whether or not the amounts so paid have in fact been kept separate and apart from UHN’s money, assets or revenues. 

2.4 No Other Funding. Without the prior written consent of MBI, UHN and the Principal Investigators agree not to use any funds received from any
Person (as defined below) other than UHN or MBI (a “Third Party”) to support any work specifically performed under the Additional Research Program whereby any rights to the Intellectual Property arising from the Additional Research
Program under this Agreement is or shall be granted to, or is otherwise optioned to, any third party other than MBI. MBI hereby consents to the use of CIHR funding for the Additional Research Program, which the Parties acknowledge will not affect
the allocation of ownership between UHN and MBI of Intellectual Property arising from the Additional Research Program under this Agreement. 

2.5 Definition of “Successful Completion”. In this Agreement, “Successful Completion” means material completion by UHN
of their work under each relevant Phase of the Additional Research Program within the relevant time period prescribed in Schedule A; provided that, in respect of each Phase of the Additional Research Program, in the event that there is: 

 

	(a)	[*] 

  

	(b)	the occurrence of an act of force majeure, as outlined in Section 13.14 below, or an event which is unforeseeable, or 

 

	(c)	any other reasonable delay not contemplated in (a) or (b) above, 

resulting in UHN not being reasonably able to complete, using reasonable commercial efforts, within the prescribed time period its obligations for
Successful Completion thereof, then MBI and UHN shall promptly and in good faith negotiate an extension to such time period to reflect the delay caused by the act in question to allow UHN a time period to fulfill, using reasonable commercial
efforts, its obligations as outlined in Schedule A, including its obligations for Successful Completion. In particular, Successful Completion means: 
  

	(d)	in respect of Phase 1: 

  

	 	(i)	[*] 

  

	 	(A)	[*] 

  

	 	(B)	[*] 

  

	 	(ii)	[*] 

  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 3 

	 	(iii)	[*] 

  

	(e)	in respect of Phase 2: 

  

	 	(i)	[*] 

  

	 	(ii)	[*] 

  

	 	(iii)	[*] 

  

	(f)	in respect of Phase 3: 

  

	 	(i)	[*] 

  

	 	(ii)	[*] 

  

	 	(iii)	[*] 

 subject in each case to the completion and
delivery of all data and a detailed report pursuant to Subsection 4.2(b), in form and substance reasonably acceptable to MBI. 
 2.6 Method
of Payment. Payment to be made by MBI hereunder shall be made by certified cheque payable to the order of “University Health Network” and sent to the following address: 

University Health Network 

Technology Development & Commercialization 

College Street - Suite 150 

Heritage Building - MaRS Centre 

Toronto, Ontario, Canada, M5G 1L7 

Attention: Cheryl Adamo - Compliance Specialist 

2.7 Currency. All monetary amounts in this Agreement are in Canadian funds. 

 

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 4 

 2.8 Interest. All monies payable to UHN hereunder and not paid when due bear interest at the then
prime rate of interest quoted by the Bank of Canada plus two (2) percentage points per annum until the date paid to UHN. UHN will be entitled to that interest in addition to any other rights or remedies available to it in respect to default in
payment by MBI. 
 ARTICLE 3 - CLINICAL DATA AND PATIENT SAMPLES 

3.1 Clinical Data. As more fully outlined in Schedule A, UHN shall utilize the Clinical Data (as such term is defined below in Subsection 5.1(a))
to undertake the analysis under the Additional Research Program and shall collaborate with MBI in analyzing the results of such analysis. Notwithstanding the foregoing, the disclosure to MBI of the raw Clinical Data is in the sole discretion of UHN.
Also notwithstanding the foregoing, UHN shall in good faith deliver to MBI, or directly to the relevant patent or regulatory agencies under assurances of confidentiality, the Clinical Data reasonably required to be disclosed in any Patent or
regulatory filings, including, in respect of the latter, that under the Clinical Laboratory Improvement Amendments regulations and program for the regulation in the United States of laboratory testing administered by the Centers for
Medicare & Medicaid Services (CMS), or the United States Food and Drug Administration regulations, or any successor agencies thereof, or other regulations in the United States or other jurisdictions, in respect of the submission for, or the
receipt of, regulatory approval or clearance of a Licensed Product. 
 3.2 Retention of Samples. Subject to availability, UHN will use
reasonable efforts to retain tissue samples and related materials utilized in the Additional Research Program. The availability of such tissue samples and related materials shall be determined solely by UHN. Notwithstanding the foregoing, UHN and
MBI shall negotiate in good faith terms and conditions (including, without limitation, financial compensation) in respect of the isolation and storage of mRNA samples for transfer to MBI. 

ARTICLE 4 - COMMUNICATION, RECORDS AND REPORTS 

4.1 Communication. The Parties are encouraged to informally communicate with each other during the course of the research activities to keep the
other apprised of their activities and of the progress of the Additional Research Program. Sandy Der, Ph.D. shall be the initial UHN contact person in respect of all such informal communications pertaining to the Additional Research Program.

 4.2 Records; Reports; Deliverables. UHN and the Principal Investigators shall keep and maintain complete and accurate written records
of the performance of the Additional Research Program, including, without limitation, records of all data, reports, deliverables and inventions. In addition to the informal communication noted above, UHN will provide to MBI by email the following
reports and deliverables: 
  

	(a)	within two (2) weeks after the end of each quarter during the Additional Research Program, a progress report (approximately five pages) summarizing the work
completed during the preceding quarter, including, among other relevant matters, details of the activities undertaken and the accomplishments achieved and challenges faced, progress made in light of the requirements for Successful Completion and the
deliverables outlined in Schedule A in respect of the particular Phase of the Additional Research Program and the development of any Intellectual Property. The Principal Investigators (and their research team, where applicable) and MBI will, as soon
as reasonably practicable after the receipt by MBI of each report, convene a meeting by either by conference or video whereby UHN will present to MBI on the contents of the report and a discussion will ensue; and 

 

	(b)	within two (2) weeks after the completion of each Phase of the Additional Research Program: 

 

	 	(i)	a detailed report (approximately five to seven pages) setting out the results of the research completed during the relevant Phase compared to the deliverables outlined
in the Additional Research Program (and, in particular, evidence of whether or not UHN has achieved Successful Completion described in Section 2.5 above for the Phase), and the development of any Intellectual Property; and

  

 5 

	 	(ii)	copies of all Intellectual Property forming a part of the Additional Licensed Technology arising from the relevant Phase of the Additional Research Program, all in a
form and with content reasonably satisfactory to MBI as required to enable MBI’s reasonably competent staff to further develop and commercialize such technology, including the transfer of such technology to a third party.

 The results outlined in the report shall be consistent in detail with those found in the publication, in respect
of the Licensed Technology, entitled “Three-gene prognostic classifier for early-stage non-small-cell lung cancer”, Lau, K., et al. (2007), Journal of Clinical Oncology. The Principal Investigators (and their research team, where
applicable) and MBI will, as soon as reasonably practicable after the receipt by MBI of each detailed report under this subsection, convene an in-person meeting at UHN’s facilities whereby UHN will make a presentation to MBI on the contents of
the report and a discussion will ensue during which UHN will address technical issues raised by MBI regarding the information so provided. 

4.3 Site Visits. Subject to UHN’s consent in its sole discretion, acting reasonably, MBI’s representatives may, on reasonable notice,
visit UHN’s facilities at reasonable times during normal business hours to observe the performance of the Additional Research Program and discuss the progress and results thereof with the Principal Investigators and their research team, where
applicable. UHN will assist MBI in scheduling such visits. 
 ARTICLE 5 - CONFIDENTIAL INFORMATION 

5.1 Definitions. In this Agreement: 
  

	(a)	“Clinical Data” means the personal and/or patient-related information and data which may be disclosed by UHN to MBI under this Agreement and/or the
Exclusive License Agreement; 

  

	(b)	“Confidential Information” of a party means any and all information of and disclosed by a Party and/or any of its Affiliates (a “Disclosing
Party”) which has or will come into the possession or knowledge of the other Party and/or any of its Affiliates (a “Receiving Party”) in connection with or as a result of entering into this Agreement and which is marked as
confidential or is identified as confidential at the time of disclosure, including information concerning the Disclosing Party’s past, present and future business, research and development, technology, customers and suppliers. For the purposes
of this definition, “Confidential Information” may include any and all Intellectual Property, Additional Licensed Technology, product, commercial, research, scientific, customer or market information and analyses or conclusions drawn or
derived therefrom; the Disclosing Party’s raw materials, processes, formulations, analytical procedures, methodologies, products, samples, specimens, functions, Know-how, data, patents, copyrights, trade secrets, processes, techniques,
programs, designs, formulae, marketing, advertising, financial, commercial, sales or programming materials, written materials, compositions, drawings, diagrams, computer programs, studies, work in progress, visual demonstrations, ideas, concepts,
and other data, in oral, written, graphic, electronic, or any other form or medium whatsoever. All Clinical Data shall be considered UHN Confidential Information, save and except for such Clinical Data reasonably required to be included in a
manuscript for acceptance of publication made in accordance with Section 5.6. Information shall not be considered “Confidential Information” to the extent that, when considered as a whole and in the context disclosed, the
information: 

  

	 	(i)	is part of the public domain at the time of disclosure, 

  

	 	(ii)	subsequently becomes part of the public domain through no act or fault of the Receiving Party or its agents or employees, 

 

	 	(iii)	can be demonstrated by the Receiving Party’s written records to have been known or otherwise available to the receiving party prior to the disclosure by the
Disclosing Party, 

  

	 	(iv)	can be demonstrated by the Receiving Party’s written records to have been subsequently provided to the receiving Party, without restriction, by a Third Party who
is not under a duty of confidentiality respecting the information disclosed and who has a legal right to disclose it, 

  

 6 

	 	(v)	can be demonstrated by the Receiving Party’s written records was subsequently and independently developed by employees or consultants of the Receiving Party who
had no knowledge of or access to the information disclosed, 

  

	 	(vi)	is required to be disclosed by law or an order of a court, tribunal, or government agency, provided that the Receiving Party gives to the Disclosing Party prompt notice
of the required disclosure in order to allow the Disclosing Party reasonable opportunity to seek a confidentiality order or the like, 

  

	 	(vii)	is reasonably required to be disclosed by MBI in any Patent filings or under the Clinical Laboratory Improvement Amendments regulations and program for the regulation
in the United States of laboratory testing administered by the Centers for Medicare & Medicaid Services (CMS), or the United States Food and Drug Administration regulations, or any successor agencies thereof, or other regulations in the
United States or other jurisdictions, in respect of the submission for, or the receipt of, regulatory approval or clearance of a Licensed Product, or 

  

	 	(viii)	is identified in writing by the disclosing Party as no longer constituting Confidential Information; and 

 

	(c)	“Person” means and includes any individual, corporation, partnership, firm, joint venture, syndicate, association, trust, government body and any other
form of entity or organization. 

 5.2 Confidentiality. It is contemplated that in the course of the performance of this
Agreement each Party may, from time to time, disclose Confidential Information to the other. Each Party agrees that it shall take all proper measures, and at least the same measures as it takes in respect of its own Confidential Information, to keep
and use in strict confidence all Confidential Information of the other Party and to not, without the prior written consent of the other Party, disclose any such Confidential Information to any Person other than its Affiliates, corporate counsel,
employees, sub-licensees, distributors and contractors who are under an obligation of confidentiality on terms substantially similar to those set out in this Agreement, who have been informed of the confidential nature of the Confidential
Information and as is reasonably required for the development and commercialization of the Additional Licensed Technology under this Agreement. In respect of the Clinical Data, MBI shall comply with all applicable laws, regulations and governmental
guidelines in respect of the protection of personal and/or patient-related information and data. Neither Party will use or disclose to any other Person any of the Confidential Information except as expressly permitted hereunder. 

5.3 Disclosure to Advisors. Notwithstanding the confidentiality obligations herein, each Party shall be permitted to disclose the terms of this
Agreement and information relating to the Additional Licensed Technology, without the prior written consent of the other Party, to advisors, shareholders, investors, potential investors, underwriters and others on a need to know basis under
circumstances that reasonably ensure the confidentiality thereof, or to the extent required by law. 
 5.4 Ownership of Confidential
Information. All Confidential Information disclosed by one party to the other shall remain the Intellectual Property of the disclosing party. 

5.5 Publicity; Use of Names. 
  

	(a)	Neither Party shall (i) use the name, trade-mark or trade-name of the other Party in connection with any public statements or disclosures, or the marketing or
advertising of any Licensed Products, or (ii) issue any press release, public announcement or any disclosure in respect of this Agreement and the Exclusive Licence Agreement and any matter associated therewith, without the prior consent of the
other Party, not to be unreasonably withheld. At the request of UHN or MBI respectively, MBI or UHN shall acknowledge the contribution and ownership of UHN and/or MBI to the Additional Licensed Technology, Improvements by UHN PI(s), Improvements by
UHN non-PI(s) or Improvements by MBI, as the case may be. 

  

 7 

	(b)	Notwithstanding the foregoing, each Party shall have a right to issue press releases, public announcements or publications, without consent of (but with notice to) the
other Party to the extent that information in any such press release, public announcement or publication has been previously made public or released or to the extent as may be legally required by, for example, the rules and regulations of the
Canadian provincial securities regulators or similar federal, provincial, state or foreign authorities, as determined in good faith by the disclosing Party. 

5.6 Publication / Principal Investigators as Lead Publishers. Principal Investigators / UHN or MBI may publish the data and/or results of the
Additional Research Program in accordance with normal academic practices but subject to the following conditions: 
  

	(a)	the publishing Party shall grant to the other Party a thirty (30) day period to review any proposed publication of the publishing Party in respect of said
Additional Research Program results; 

  

	(b)	during this review period, the other Party may by notice to the publishing Party: 

 

	 	(i)	require the publishing Party to remove any of the other Party’s Confidential Information, or 

 

	 	(ii)	request a delay in the publication for up to a maximum of an additional sixty (60) days in order to protect the other Party’s proprietary interests;

  

	(c)	for purposes of certainty and clarity, the publishing Party may publish the data and/or results of the work undertaken under the Additional Research Program after the
aforementioned thirty (30) day review period in the absence of any requirement to remove the other Party’s Confidential Information (further to Paragraph (b)(i) above) or after sixty (60) days if the other Party requests a delay of
the publication to protect the other Party’s proprietary interests (further to Paragraph (b)(ii) above); 

  

	(d)	the publishing Party shall recognize in all publications any relevant contributions of UHN and MBI. Subject to Subsection 5.6(e) below, authorship shall be determined
in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals of the International Committee of Medical Journal Editors (http://www.icmje.org/), or such other practices that are customary for academic
publications, as mutually agreed by the Parties, acting reasonably; 

  

	(e)	the Parties acknowledge that, to facilitate the commercialization of the Licensed Technology, it is essential for the results of the Additional Research Program to be
published in a timely fashion in peer-reviewed journals. Notwithstanding Subsections 5.6(a) to 5.6(d) above, the Parties agree and acknowledge that it is in their best interests, and they fully intend, for the Principal Investigators / UHN to lead,
to the extent that they desire to do so, all publications in respect of the data and/or results of the Additional Research Program. To that extent, MBI shall provide to UHN advance notice of its desire to have published certain data and/or results
of the Additional Research Program. MBI shall not proceed with any proposed publication until the earlier of the Principal Investigators / UHN declining to lead such publication or the expiration of thirty (30) days after the Principal
Investigators’ / UHN’s receipt of such notice from MBI, after which MBI may pursue the proposed publication in accordance with Subsections 5.6(a) to 5.6(d) above and Principal Investigators / UHN shall provide to MBI all reasonable
assistance and relevant data and analysis to facilitate such timely publication. For all publications to be led by the Principal Investigators / UHN , Principal Investigators / UHN shall pursue all such publications in a timely manner in accordance
with Subsections 5.6(a) to 5.6(d) above, and MBI shall provide to UHN all reasonable assistance and relevant data and analysis to facilitate such timely publication. 

5.7 Duration of Obligation. Unless otherwise agreed by the Parties in writing, the obligations of the Parties relating to Confidential Information
set out in this Article 5 shall survive the expiration or termination of this Agreement for a period of ten (10) years. 

ARTICLE 6 - INTELLECTUAL PROPERTY 

6.1 Definitions. In this Agreement: 
  

	(a)	“Additional Licensed Patents” means the Patents described in and/or listed in Schedule A, as amended from time to time; 

 

 8 

	(b)	“Additional Licensed Technology” means: 

  

	 	(i)	the UHN Additional Existing IP, 

  

	 	(ii)	the UHN Additional Research Program IP, and 

  

	 	(iii)	the Joint Additional Research Program IP, 

but excluding any Improvements by UHN PI(s) and any Improvements by UHN non-PI(s) and UHN Other IP, unless expressly agreed in writing by
the Parties to be included hereunder pursuant to the Additional Exclusive License Agreement; 
  

	(c)	“Improvements by MBI” means any and all improvements to the Additional Licensed Technology made by MBI, its employees and consultants, outside of the
Additional Research Program after the Effective Date, which claim priority to or otherwise rest on claims of the Additional Licensed Patents described in and/or listed in Section 1 of Schedule C, as amended from time to time.

  

	(d)	“Improvements by UHN PI(s)” means any and all improvements to the Additional Licensed Technology developed at UHN by the Principal Investigators (and
the UHN personnel, employees, staff members, students, agents and consultants under their direct supervision) outside of the Additional Research Program after the Effective Date, which claim priority to or otherwise rest on claims of the Additional
Licensed Patents described in and/or listed in Section 1 of Schedule A, as amended from time to time; 

  

	(e)	“Improvements by UHN non-PI(s)” means any and all improvements to the Additional Licensed Technology developed at UHN by UHN personnel other than the
Principal Investigators (and the UHN personnel, employees, staff members, students agents and consultants under their direct supervision) outside of the Additional Research Program after the Effective Date, which claim priority to or otherwise rest
on claims of the Additional Licensed Patents described in and/or listed in Section 1 of Schedule A, as amended from time to time; 

  

	(f)	“Intellectual Property” means inventions, discoveries, written material, compounds, patentable and unpatentable information, Know-how, trade secrets,
copyright, designs, plant breeders’ rights, integrated circuit topographies, ideas (including but not limited to any computer software), formulae, algorithms, concepts, proprietary data, techniques, instructions, processes, expert opinions,
information, materials, program listings, flow charts, logic diagrams, manuals, specifications, instructions, or any copies of the foregoing in any medium, or the expression thereof; 

 

	(g)	“Intellectual Property Rights” means any proprietary, possessory, use and ownership rights, titles and interests (whether beneficial or legal) of all
kinds whatsoever, in and to any Intellectual Property, including by way of Patents, Patent applications, trade-marks, trademark applications, copyrights, copyright applications, industrial designs, industrial design applications, Know-how and trade
secrets, and all other intellectual and industrial property rights whatsoever and world-wide (whether registered or unregistered and including rights in any application for any of the foregoing); 

 

	(h)	“Joint Additional Research Program IP” means any and all Intellectual Property conceived or developed with contributions by both UHN and MBI (which
includes their respective personnel, staff members, employees, students, agents and consultants) pursuant to activities conducted in respect of the Additional Research Program under the Additional Sponsored Research Agreement, including, without
limitation, the Additional Licensed Patents described in and/or listed in Section 3 of Schedule C, as amended from time to time; 

  

	(i)	“Know-how” means any information pertaining to a technology which is not disclosed in a patent or published patent application, and includes
trade-secrets; 

  

	(j)	“MBI Additional Research Program IP” means any and all Intellectual Property conceived or developed solely by MBI (which includes its personnel, staff
members, employees, students, agents and consultants) pursuant to activities conducted specifically in respect of the Additional Research Program under this Agreement; 

 

 9 

	(k)	“Patent” shall mean: 

  

	 	(i)	any issued patent or patent application, 

  

	 	(ii)	all continuations and continuations-in-part applications to the issued patent or patent application set out in Paragraph (i) (solely to the extent such
continuations-in-part applications contain subject matter on which claims issuing obtain the benefit of a priority date of any patent or patent application set out in Paragraph (i)), 

 

	 	(iii)	all divisions, patents of addition, reissues, renewals and extensions of any of the patent, patent application, continuations and continuations-in-part applications set
out in Paragraphs (i) and (ii), and 

  

	 	(iv)	all foreign counterparts of any of the foregoing (including, without limitation, European Supplementary Protection Certificates or its equivalent);

  

	(l)	“UHN Additional Existing IP” means UHN’s pre-existing background Intellectual Property relevant to the Additional Research Program, including,
without limitation, the Additional Licensed Patents described in and/or listed in Section 1 of Schedule C, as amended from time to time, and the relevant Clinical Data; and 

 

	(m)	“UHN Additional Research Program IP” means any and all Intellectual Property conceived or developed solely by UHN (which includes its personnel, staff
members, employees, students, agents and consultants) pursuant to activities conducted specifically in respect of the Additional Research Program under this Agreement, including, without limitation, the Additional Licensed Patents described in
and/or listed in Section 2 of Schedule C, as amended from time to time. 

 6.2 Background Intellectual Property. Each
Party’s pre-existing background Intellectual Property relevant to the Additional Research Program (comprising UHN Additional Existing IP and MBI Existing IP) and any other Intellectual Property developed independently of, or arising from
activities not solely and specifically conducted pursuant to the conduct of, the Additional Research Program by a Party (the latter hereinafter referred to as “UHN Other IP” and “MBI Other IP” respectively), shall
be owned by that Party. For purposes of certainty and clarity, 
  

	(a)	UHN Other IP shall include, but not be limited to, all Intellectual Property generated or otherwise created by UHN and/or Principal Investigator(s) related to:

  

	 	(i)	prognostic and/or diagnostic genetic-based approaches and/or methodologies of general application, 

 

	 	(ii)	prognostic and/or diagnostic DNA-based approaches and/or methodologies for any application, and 

 

	 	(iii)	prognostic and/or diagnostic protein-based approaches and/or methodologies for any application, 

and UHN Other IP shall exclude prognostic mRNA expression-based signatures for the clinical management of lung cancers; and 

 

	(b)	UHN Additional Research Program IP, MBI Additional Research Program IP and Joint Additional Research Program IP shall not include or otherwise encompass UHN Other IP.
Other than as set out in this Agreement and the Additional Exclusive License Agreement, no Party shall obtain any rights in another Party’s background Intellectual Property or Other IP. 

6.3 Additional Research Program Intellectual Property. Subject to Section 6.2: 

 

	(a)	UHN shall solely own all right, title and interest in and to all UHN Additional Research Program IP; 

 

 10 

	(b)	MBI shall solely own all right, title and interest in and to all MBI Additional Research Program IP; and 

 

	(c)	UHN and MBI shall jointly own all right, title and interest in and to Joint Additional Research Program IP. 

6.4 Disclosure of Inventions. 
  

	(a)	Each Party shall disclose to the other Party any patentable Intellectual Property conceived and reduced to practice in the conduct of the Additional Research Program
that may form the subject matter of a Patent (each, an “Invention”), as set out herein. In respect of UHN, a Principal Investigator shall disclose to UHN in writing, in accordance with UHN’s intellectual property policy, any
potential Invention made by UHN. UHN shall formally disclose the Invention to MBI by written notice in accordance with UHN’s intellectual property policy. In respect of MBI, MBI shall provide written notification to UHN of any potential
Invention made by MBI via an analogous written notice (hereinafter, said written notices referred to as an “Invention Notice”). 

  

	(b)	Within sixty (60) days after a Party receives an Invention Notice from the other Party, the Parties shall meet to discuss whether to pursue Patent protection and,
if and/or as appropriate, their respective roles and responsibilities (including financial) in respect of this pursuit of Patent protection. Subject to the terms of the Additional Exclusive License Agreement, and absent any additional agreement(s)
between the Parties: 

  

	 	(i)	each Party shall have sole responsibility for the prosecution and/or maintenance of any application and/or registration for any Intellectual Property Rights solely
owned by it; and 

  

	 	(ii)	the Parties shall have joint responsibility for the prosecution and/or maintenance of any application and/or registration for Intellectual Property Rights jointly owned
by the Parties. 

 6.5 Research Licenses. The Parties shall, and do hereby grant to each other all required licenses (on a
non-exclusive, non-sublicenseable, royalty-free, for research and development purposes only basis) in respect of an individual Party’s Intellectual Property necessary for the other Party to conduct the activities contemplated hereunder this
Agreement. 
 6.6 Commercialization Licenses. The granting of licenses by one Party to the other in regards to the commercialization of
Intellectual Property arising from the activities conducted pursuant to this Agreement and in respect of a Party’s background Intellectual Property shall be governed by the terms and provisions of the Additional Exclusive License Agreement.

 6.7 Avoidance of Third Party Rights. Subject to Section 6.10, neither UHN nor the Principal Investigators shall knowingly engage
in any activities, on their own or in collaboration with a third party, or use any third party facilities or third party Intellectual Property in performing the Additional Research Program which could result in any claims of any ownership interest
in any inventions being made by such third party, without MBI’s prior written consent. 
 6.8 Intellectual Property Representations and
Warrantees. The Parties acknowledge that neither Party makes any representation or warranty with respect of the following: 
  

	(a)	whether any third party may have any right or interest in any Intellectual Property arising out the Additional Research Program; 

 

	(b)	whether any Invention will be covered by any Patent or Patent application or any other form of Intellectual Property registration. 

The Parties further acknowledge that it may be necessary to reach agreements with Third Parties in order to permit the use and exploitation of the
results of the Additional Research Program and of any Intellectual Property arising therefrom. To the best of the knowledge of UHN as on the Effective Date, neither UHN nor the Principal Investigators are aware of any Intellectual Property Rights of
any Third Party in or to any Intellectual Property relating to the Additional Licensed Technology. 
  

 11 

 6.9 Infringement. The Parties acknowledge and agree that the terms of the Additional Exclusive
License Agreement shall govern the prosecution and defense of any actions relating to any alleged infringement of the Additional Licensed Technology by third parties or any alleged infringement of third party Intellectual Property by the Additional
Licensed Technology. 
 6.10 Other Research. MBI acknowledges that: 

 

	(a)	UHN (for purposes of this Section 6.10, namely personnel, staff and employees other than the Principal Investigators); and 

 

	(b)	the Principal Investigators; 

 have received
and/or shall continue to receive, funding from other sources (in addition to the Canadian Institutes of Health Research (“CIHR”) funding to be applied to the Additional Research Program) to conduct similar and/or related research to
that contemplated by the Additional Research Program. MBI acknowledges that it shall not have any claim to the work product of the other sources of funding (other than CIHR funding within the Additional Research Program) in law or otherwise, other
than the option described in Section 6.11 below or as may be separately negotiated and agreed to by the Parties. 
 6.11 Option for
Independent Inventions. 
  

	(a)	UHN hereby grants to MBI a right of first negotiation for an exclusive, royalty-bearing license, with the right to grant sublicenses without consent, for the
commercialization of any Intellectual Property pertaining to prognostic mRNA expression-based tests for use in the clinical management of lung cancers, developed by UHN during the term of this Agreement independently of the Additional Licensed
Technology and the Additional Research Program (each, an “Independent Invention”), exercisable in accordance with Subsection 6.11(b), provided that such right of first negotiation and any resulting license will be subject to
Section 6.12. 

  

	(b)	UHN will provide MBI with written notice disclosing each Independent Invention promptly after UHN files a Patent application for such Independent Invention, which
notice shall be accompanied by sufficient data and other information to enable MBI to evaluate such Independent Invention (a “Notice of Independent Invention”). MBI will have a period of six (6) months after receiving each
Notice of Independent Invention from UHN to provide written notice to UHN of its intent to license the disclosed Independent Invention (“Notice of Intent”). If UHN does not receive a Notice of Intent within such six (6) month
period, MBI’s right of first refusal will lapse and UHN shall be free to license or otherwise exploit the Independent Invention in its sole discretion without any further notice to MBI, and MBI shall have no further claim on, or to, the
Independent Invention. After a Notice of Intent has been received, both Parties shall diligently and in good faith negotiate the addition of such Independent Invention to the Additional Exclusive License Agreement or the licensing thereof under a
separate license agreement. Any such separate license shall be on terms and conditions that are consistent with other such licenses within the industry and satisfactory to UHN. If the Parties have not agreed on the license agreement within nine
(9) months of receipt of a Notice of Intent, UHN shall be free to license or otherwise exploit the Independent Invention in its sole discretion, on terms not more favourable to the licensee than the most favourable terms offered to MBI, without
any further notice to MBI, and MBI shall have no further claim on, or to, the Independent Invention. 

  

	(c)	This Section 6.11 shall survive the expiration or earlier termination of this Agreement for a period of one (1) year. 

6.12 Third Party Rights. Each right of first negotiation and each license granted to MBI by UHN in and to any Independent Inventions under
Section 6.11 will be subject to the following Third Party Intellectual Property Rights: 
  

	(a)	for any Independent Invention developed by one or both Principal Investigators or those UHN employees, personnel, staff and students under their direct supervision:

  

	 	(i)	any Third Party Intellectual Property Rights existing on or before October 19, 2007 (the “Reference Date”), and 

 

 12 

	 	(ii)	any Third Party Intellectual Property Rights arising after the Reference Date pursuant to a research program initiated and funded from inception by a Third Party
pursuant to a written research agreement; and 

  

	(b)	for any Independent Invention developed by any UHN employees, personnel, staff or students, other than those noted in Subsection 6.12(a), any Third Party Intellectual
Property Rights. 

 For each Independent Invention for which MBI has a right of first negotiation, UHN and MBI shall cooperate and
work together, prior to any Third Party being granted any interest in the Intellectual Property Rights in such Independent Invention, to review the merits of any claims made by any Third Parties to the Intellectual Property Rights in such
Independent Invention. For each Independent Invention for which MBI has delivered a Notice of Intent, and for which no Third Party claim is substantiated, UHN and MBI shall in good faith negotiate a license to MBI for the Intellectual Property
Rights in the Independent Invention. UHN shall keep MBI apprised of any facts that may arise from time to time where a Third Party may have or make a claim to Intellectual Property Rights in any Independent Invention. If a Third Party makes an
unsubstantiated claim to Intellectual Property Rights in an Independent Invention, UHN and MBI shall cooperate on the appropriate course of action to defend against any such claim or challenge, restrain or enjoin any Intellectual Property Rights
asserted by the Third Party in UHN’s discretion, acting reasonably, and in good faith in order to protect MBI’s interests in such Intellectual Property Rights. UHN shall take the lead in discussions with any Third Parties relating to any
such claims; provided that, in the unlikely event of litigation, MBI shall have the right to control any such litigation, including the right to settle any dispute in any manner it deems expedient, and UHN shall reasonably assist MBI in connection
therewith. 
 6.13 Current Research of Principal Investigators. UHN represents and warrants that, as of the Reference Date and continuing
to the Effective Date, the Principal Investigators and those UHN employees, personnel, staff and students under their direct supervision have not developed, and/or are not developing (other than in respect of the Licensed Technology and the
Additional Licensed Technology and the technology being developed under the Research Program and the Additional Research Program) any technology or Intellectual Property similar to the Additional Licensed Technology specifically encompassing
prognostic mRNA expression-based signatures to be used in the clinical management of lung cancers, other than that listed in Schedule D attached hereto (which information MBI shall keep strictly confidential as per the confidentiality provisions
outlined in Article 5 hereto). 
 6.14 Current Research of Other UHN Researchers. UHN represents and warrants that, to the best of
UHN’s knowledge as on the Effective Date, no UHN staff member, researcher or employee (excluding the Principal Investigators and those UHN employees, personnel, staff and students under their direct supervision) has developed, and/or are
developing, as of the Reference Date and continuing to the Effective Date, any technology or Intellectual Property similar to the Additional Licensed Technology specifically encompassing prognostic mRNA expression-based signatures to be used in the
clinical management of lung cancers. 
 ARTICLE 7 - INDEMNIFICATION 

7.1 Mutual Indemnity. Subject to Article 8 below, each Party agrees to be responsible and to assume liability for its acts or omissions, and those
of its officers, agents, personnel, employees, staff or students, arising out of or as a result of, or in connection with the conduct of the Additional Research Program, to the full extent required by law. A Party that is negligent or that breaches
this Agreement agrees to indemnify, defend and hold the other Party harmless from liability resulting from its negligence or breach, including, without limitation, legal fees and costs, except to the extent caused by the other Party, and each Party
agrees to maintain reasonable insurance coverage for such liabilities. 
  

 13 

 ARTICLE 8 - REPRESENTATIONS, WARRANTEES & LIABILITY 

8.1 General Representations. Each Party represents and warrants to the other Party that it 

 

	(a)	is duly incorporated and organized and validly existing under the laws of its jurisdiction of incorporation and has all requisite corporate power and authority to enter
into and perform its obligations under this Agreement; and 

  

	(b)	has taken all necessary corporate action, steps and proceedings to approve or authorize, validly and effectively, the execution and delivery of this Agreement and the
performance of its obligations hereunder. 

 8.2 NO WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER
PARTY, NOR THE PRINCIPAL INVESTIGATORS, MAKES ANY WARRANTIES, REPRESENTATIONS OR GUARANTEES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, REGARDING THE ADDITIONAL RESEARCH PROGRAM AND ANY INTELLECTUAL PROPERTY, INVENTIONS OR PRODUCTS ARISING
THEREFROM TO BE SUPPLIED UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF ORIGINALITY OR ACCURACY OR ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. MBI ACKNOWLEDGES THAT IT ASSUMES THE
ENTIRE RISK FOR THE DESIGN, DEVELOPMENT, MANUFACTURE, SALE OR OTHER DISPOSITION AND PERFORMANCE OF PRODUCTS INCORPORATING INTELLECTUAL PROPERTY ARISING FROM THE ADDITIONAL RESEARCH PROGRAM. 

8.3 NO CONSEQUENTIAL DAMAGES. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY, NOR THE PRINCIPAL
INVESTIGATORS, BE LIABLE FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL, OR INCIDENTAL DAMAGES OR LOST PROFITS, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY, SUFFERED BY THE OTHER PARTY OR ANY THIRD PARTY RESULTING FROM THE USE OF THE RESULTS OF THE
ADDITIONAL RESEARCH PROGRAM, OR ANY INTELLECTUAL PROPERTY, INVENTIONS, PRODUCTS OR PATENTS ARISING THEREFROM. 
 ARTICLE 9 -
TERM AND TERMINATION 
 9.1 Term. This Agreement shall commence on the Effective Date and continue for a period of two (2) years
thereafter unless extended or earlier terminated as set out below. Each extension or renewal of this Agreement shall require the prior written approval of the Parties. 

9.2 Termination by UHN. UHN may terminate this Agreement on written notice to MBI: 

 

	(a)	if prior to the completion of Phase I of the Additional Research Program, MBI fails to meet any of its material obligations under this Agreement and does not remedy
these failures within thirty (30) days after receipt of notice of such failure from UHN; 

  

	(b)	if subsequent to the completion of Phase I of the Additional Research Program, MBI fails to meet any of its material obligations under this Agreement and does not
remedy these failures within ninety (90) days after receipt of notice of such failure from UHN; or 

  

	(c)	immediately upon UHN giving notice to MBI at any time: 

  

	 	(i)	MBI files a voluntary petition in bankruptcy or insolvency or shall petition for reorganization under any bankruptcy law, or makes a general assignment for the benefit
of creditors, or otherwise acknowledges insolvency or is adjudged bankrupt, 

  

	 	(ii)	MBI shall consent to an involuntary petition in bankruptcy or if a receiving order is given against it under the Bankruptcy and Insolvency Act (or such other equivalent
Act in the respective jurisdiction), or 

  

 14 

	 	(iii)	the appointment of a receiver or other similar representative for MBI by a court of competent jurisdiction. 

9.3 Termination by MBI. MBI may terminate this Agreement on written notice to UHN: 

 

	(a)	immediately in the event that one or more Principal Investigators unable to continue the direction of the Additional Research Program as described under
Section 1.2, and no replacement satisfactory to MBI has been found; 

  

	(b)	immediately at any time after UHN fails to achieve Successful Completion of any Phase of the Additional Research Program within the timelines set out in Schedule A or
such other timelines as may be agreed to by the Parties; 

  

	(c)	immediately at any time after achievement of Successful Completion of any Phase of the Additional Research Program, if MBI determines, in good faith and utilizing sound
and reasonable business practice and judgment, that in light of the results of the Additional Research Program the further development and commercialization of the Additional Licensed Technology under the Additional Research Program is not
advisable; 

  

	(d)	immediately in accordance with Section 9.6; or 

  

	(e)	if UHN fails to meet any of its other material obligations under this Agreement and does not remedy these failures within thirty (30) days after receipt of notice
of such failure from MBI. 

 9.4 Payment of Outstanding Expenses Upon Termination. Upon termination of this Agreement, the
funds provided by MBI under the MBI Grant shall be applied only to expenses outlined in Schedule B incurred by the Principal Investigators as of the date of notice of termination provided by MBI or UHN, as the case may be. Any amounts held by UHN on
account of the MBI Grant which are in excess of the expenses incurred shall be promptly repaid to MBI. 
 9.5 Effect of Termination. In
the event of the expiration or early termination of this Agreement: 
  

	(a)	upon receipt of notice of termination, UHN shall immediately cease all further work with respect to the Additional Research Program; 

 

	(b)	all of UHN’s rights to use the Confidential Information of MBI shall terminate and UHN shall return to MBI all parts of the Confidential Information of MBI and any
copies thereof in the possession or control of UHN, the Principal Investigators or their research team; 

  

	(c)	if the Additional Exclusive License Agreement is terminated, all of MBI’s rights to use the Confidential Information of UHN shall terminate and MBI shall return to
UHN all parts of the Confidential Information of UHN and any copies thereof in the possession or control of MBI; 

  

	(d)	if the Additional Exclusive License Agreement survives the termination of this Agreement: 

 

	 	(i)	MBI’s use of UHN’s Confidential Information will continue to be governed by the confidentiality provisions of the Additional Exclusive License Agreement; and

  

	 	(ii)	UHN shall provide to MBI copies of all Intellectual Property forming a part of the Additional Licensed Technology arising from the Additional Research Program, whether
or not complete, all in a form and with content reasonably satisfactory to MBI as required to enable MBI’s reasonably competent staff to further develop and commercialize such technology and/or transfer such technology to a third party for
further research and development. UHN shall also conduct a technical review meeting with MBI to address issues raised by MBI regarding the information so provided. 

9.6 Suspension of Additional Research Program by MBI. 
  

	(a)	After the completion of Phase I of the Additional Research Program, and the payment of the Phase I Additional Research Program success fee in the event of Successful
Completion thereof pursuant to the Additional Exclusive License Agreement, MBI may by written notice to UHN: 

  

	 	(i)	suspend the work under this Agreement, including all research work and financial support under the Additional Research Program; or 

 

 15 

	 	(ii)	immediately terminate this Agreement; 

to focus research under the Sponsored Research Agreement; provided that if the work under the Sponsored Research Agreement is suspended or
MBI has terminated the Sponsored Research Agreement in order to focus research under this Agreement, MBI may not suspend or terminate this Agreement pursuant to this Section 9.6. For greater certainly, UHN shall be eligible under the Additional
Exclusive License Agreement for payment of the Phase I Additional Research Program success fee in respect of Successful Completion thereof, notwithstanding any subsequent suspension of the work under this Agreement or the termination of this
Agreement. 
  

	(b)	At any time while the work under this Agreement is suspended, MBI may by written notice to UHN: 

 

	 	(i)	immediately terminate this Agreement; or 

  

	 	(ii)	resume the work under this Agreement, provided that MBI reimburses UHN for the direct costs incurred by UHN (and not already reimbursed by MBI) in continuing the
Additional Research Program while the work was suspended by MBI. 

  

	(c)	In the event MBI resumes the work under this Agreement, MBI and UHN shall, in good faith, discuss and mutually agree upon: 

 

	 	(i)	the scope of the work undertaken, and direct costs incurred, by UHN in continuing the Additional Research Program while the work was suspended by MBI;

  

	 	(ii)	any appropriate Additional Research Program success fees payable to UHN under the Additional Exclusive License Agreement in light of the work undertaken by UHN in
continuing the Additional Research Program while the work was suspended by MBI; 

  

	 	(iii)	the work to be undertaken by UHN to complete the remaining portions of the Additional Research Program; and 

 

	 	(iv)	any amendments to the Budget and to the applicable Additional Research Program success fees under the Additional Exclusive License Agreement to complete the remaining
portions of the Additional Research Program. 

 9.7 Survival. The Parties agree the provisions of Subsection 1.4(b),
Sections 2.8, 6.1 through 6.4, 6.6, 6.8 through 6.10, 9.5 and 9.7, and Article 3, Article 5, Article 7, Article 8, Article 10, Article 11, Article 12 and Article 13 shall remain in full force and effect after the expiration or earlier termination of
this Agreement, until such time as the Parties mutually agree to the release of the obligations contained therein. The Parties agree the provisions of Section 6.11 shall remain in full force and effect after the expiration or earlier
termination of this Agreement in accordance with the period set out therein. 
  

 16 

 ARTICLE 10 - NOTICES 

10.1 Notices. All notices which are required or permitted to be given hereunder including judicial payment notices must be in writing. All such
notices must be sent as follows: 
  

					
	If to UHN:	  	 University Health Network

College Street - Suite 150
 Heritage Building -
MaRS Centre
 Toronto, Ontario M5G 1L7, Canada

Telephone: (416) 581-7410
 Facsimile: (416)
977-4765

			
		  	Attention:	  	 Brian H. Barber, PhD,

Director, Technology
 Development &
Commercialization

		
	 With a copy to the Principal

Investigators:
	  	 Ming-Sound Tsao, MD

Princess Margaret Hospital
 7th Floor, Room 7-613

 University Avenue
 Toronto, Ontario

 Canada M5G 2M9
 Telephone: (416)
340-4737
 Facsimile: (416) 340-5517

		
		  	 Frances A. Shepherd, MD

Princess Margaret Hospital
 5th Floor, Room 5-104

 University Avenue
 Toronto, Ontario

 Canada M5G 2M9
 Telephone: (416)
946-4522
 Facsimile: (416) 946-6546

		
	If to MBI:	  	 Med BioGene Inc.

#300 – 2386 East Mall
 Gerald McGavin
Building
 Vancouver, British Columbia

Canada V6T 1Z3
 Telephone: (604)
827-5100
 Facsimile: (604) 827-5120

			
		  	Attention:	  	 Erinn B. Broshko,
 Chief
Executive Officer

 or to such other address as the recipient may have designated by notice given in accordance with this
Article 10. Any such notice may be delivered by hand, by registered mail, or sent by facsimile and will be deemed to have been delivered on the date of delivery if delivered by hand, five (5) days after mailing if sent by registered mail, or on
the first business day following the date of sending, if sent by facsimile. 
 ARTICLE 11 - DISPUTE RESOLUTION 

11.1 Dispute Resolution. In the event of any dispute, controversy or claim among the Parties arising out of or in connection with this Agreement,
or the breach thereof, or in respect of any defined legal relationship associated therewith or derived therefrom, the Parties agree to resolve the dispute in accordance with the following procedures outlined in this Article 11, subject to Subsection
11.5(d). 
 11.2 Good Faith Negotiations. A Party may notify the other Party in writing that a dispute has arisen. The Parties will, in
the first instance, attempt to resolve the dispute, controversy, claim or allegation of breach by entering into good faith negotiations. The Parties shall meet to attempt, in good faith, to resolve the dispute by negotiation, either directly or
through the assistance of such advisors as they may engage. If, within seven (7) days, the Parties do not reach agreement on the resolution of the dispute, the Parties agree to proceed to mediation as set out in Section 11.3 below.

  

 17 

 11.3 Mediation. Subject to Section 11.2, the Parties shall mediate their dispute before a
mediator who is a member of Ontario’s Mandatory Mediation Program Roster of mediators having appropriate experience in the biopharmaceutical industry. If the Parties fail to agree on a mediator within fourteen (14) days after the decision
to proceed to mediation, either Party may apply to a court of competent jurisdiction to appoint an qualified mediator having appropriate experience in the biopharmaceutical industry. Mediation shall be carried out by the mediator within twenty-one
(21) days of the mediator’s appointment. 
 11.4 Arbitration. 

 

	(a)	Subject to Sections 11.2 and 11.3, if the Parties fail to resolve their dispute within seven (7) days of the start of the mediation, the Parties will appoint
an arbitrator having appropriate experience in the biopharmaceutical industry who will conduct an arbitration of the dispute. If the Parties cannot agree on a mutually acceptable arbitrator within seven (7) days of the decision to proceed to
arbitration, either Party may apply to a court of competent jurisdiction to appoint an qualified arbitrator having appropriate experience in the biopharmaceutical industry. The arbitration shall be conducted in accordance with the Arbitration
Act, 1991 (Ontario) and the arbitrator shall also be empowered to hear injunctive proceedings in accordance therewith. 

  

	(b)	Notwithstanding Section 11.5 below, the arbitrator may include in its award an order as to the payment of the costs of the proceedings and reasonable counsel fees.
Any Party ordered to pay costs may avail itself of any procedure for the taxing of costs, provided, however, that the Parties specifically agreed that the officer taxing such costs need not be bound by any statutory scale of costs.

  

	(c)	The arbitrator will make its decision in writing within fifteen (15) days of the hearing and, unless the Parties otherwise agree, the arbitrator’s reasons
will be set out in the award. The award shall be final and binding on the Parties and shall not be subject to any appeal although either Party may request clarification of the award and the arbitrator’s reasons. 

 

	(d)	The Parties consent to the award of the arbitrator being entered in any court having jurisdiction for the purposes of enforcement. In addition, if it appears to any
Party that the arbitrator lacks the power to give effective interim relief, such Party may apply to any appropriate court for such relief. 

  

	(e)	All matters in dispute, all claims, submissions, evidence and findings, and the award itself shall be kept confidential by the arbitrator, and no information regarding
any of the foregoing will be released to any Third Party or otherwise made public without the written consent of the Parties, except as otherwise contemplated herein and except for such information which is not Confidential Information.

  

	(f)	The Parties may with mutual consent, expand or abridge the time periods provided for in this Article 11. 

11.5 General. 
  

	(a)	The expenses of the mediation or arbitration shall be borne equally by the Parties. Notwithstanding the foregoing, the mediator or arbitrator may include in his or her
award an order as to the payment of the costs of the proceedings and reasonable counsel or other advisor fees. Any Party ordered to pay costs may avail itself of any procedure for the taxing of costs; provided, however, that the Parties specifically
agree that the officer taxing such costs need not be bound by any statutory scale of costs. 

  

	(b)	All meetings and hearings will be in private unless the Parties otherwise agree. 

 

	(c)	Any Party may be represented at any meetings or hearings by legal counsel or any other advisor. 

 

	(d)	Notwithstanding this Article 11: 

  

	 	(i)	disputes relating to the sufficiency of grounds for termination under Sections 9.2 or 9.3 shall not be subject to this Article 11; and 

 

 18 

	 	(ii)	either party shall be free to submit any dispute relating to Intellectual Property to any court having jurisdiction over the Parties and the subject matter of the
dispute and to seek such relief and remedies as are available in that court. 

 ARTICLE 12 - COMPLIANCE WITH
LAWS AND REGULATIONS 
 12.1 Compliance with Laws. The Parties shall comply, and agree that the provisions of this Agreement are
intended to be interpreted and implemented so as to comply, with all applicable laws, governmental rules and regulations; however, if it is determined that any provision of this Agreement is not in such compliance, or if the UHN Research Ethics
Board or other comparable body objects to the terms of this Agreement or the provision or use of human biological material hereunder, then the Parties agree to modify that provision, or this Agreement so as to be in compliance with, or to be
acceptable to, such body. 
 ARTICLE 13 - GENERAL TERMS AND CONDITIONS 

13.1 Entire Agreement. The Parties hereto acknowledge that this Agreement and its schedules, together with the Additional Exclusive License
Agreement, set forth the entire agreement and understanding of the Parties hereto as to the subject matter hereof, and supersedes all prior discussions, agreements and writings in respect hereto. 

13.2 Schedules. The following schedules are annexed to and form part of this Agreement: 

Schedule A – Additional Research Program 

Schedule B – Budget 

Schedule C – Additional Licensed Patents 

Schedule D – Section 6.13 Disclosure 

13.3 General Assurances. The Parties hereto agree to do all such reasonable things and to execute such instruments and documents as may be
reasonably necessary or desirable in order to carry out the provisions and intent of this Agreement. 
 13.4 Enure to Benefit. This
Agreement shall enure to the benefit of and be binding upon the respective Parties hereto and, where the context admits or requires, their respective permitted successors or assigns. 

13.5 Assignment. This Agreement cannot be assigned, sold, transferred or encumbered in any manner by a Party without the expressed written consent
of the other Party, which consent will not be unreasonably withheld. 
 13.6 No Joint Venture. Each Party is and will remain at all times
independent of each other. The Parties are not and shall not be considered to be joint venturers, partners or agents of each other and neither of them shall have the power to bind or obligate the other except as set forth in this Agreement. The
Parties mutually covenant and agree that neither shall they, in any way, incur any contractual or other obligation in the name of the other, nor shall they have liability for any debts incurred by the other. No representation will be made or acts
taken by any of the Parties which could establish any apparent relationship of agency, joint venture, partnership or employment. 
 13.7
Waiver. No amendment, supplement or waiver of any provision of this Agreement shall be binding on any Party unless consented to in writing by such Party. No waiver of any provision of this Agreement shall constitute a waiver of any other
provision, nor shall any waiver constitute a continuing waiver unless otherwise expressly provided. Further, no failure or delay by any Party in exercising any right or remedy shall operate as a waiver thereof, nor shall any single or partial
exercise or waiver of any right or remedy preclude its further exercise or the exercise of any other right or remedy. 
  

 19 

 13.8 Time of the Essence. Time is of the essence in this Agreement and of each and every term and
condition hereof. 
 13.9 Headings. The headings in this Agreement are for convenience of reference only and shall not affect the
interpretation of this Agreement. Any reference in this Agreement to an article, section, sub-section or Schedule refers to the specified article, section, sub-section or schedule to this Agreement. 

13.10 Number, Gender and Persons. In this Agreement, words importing the singular number shall include the plural and vice versa, words importing
gender shall include all genders and words importing persons shall include individuals, corporations, partnerships, associations, trusts, unincorporated organizations, governmental bodies and other legal or business entities. 

13.11 Joint Preparation. This Agreement shall be deemed to be jointly prepared by the Parties, and any ambiguity herein shall not be construed for
or against any Party. 
 13.12 Governing Law. This Agreement shall be governed by the laws of the Province of Ontario and the laws of
Canada applicable therein, and shall be treated as an Ontario contract. The Parties irrevocably and unconditionally submit to the non-exclusive jurisdiction of the courts of the Province of Ontario and all courts competent to hear appeals therefrom
in connection with any matters arising under this Agreement. 
 13.13 Severability of Provisions. In the event that any provisions of
this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction in any jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision in said jurisdiction and such
determination shall not affect the validity or enforceability of such provision or the Agreement in any other jurisdiction. The Parties shall in good faith negotiate a substitute clause for any provision declared invalid or unenforceable, which
shall most nearly approximate the intent of the Parties in entering this Agreement. 
 13.14 Force Majeure. In the event that any one of
the Parties is prevented from fulfilling any of its obligations herein by acts of God, war, strikes, riots, storms, fires, governmental orders or restrictions or any other cause beyond its control, the payment of owed monies, or the applicable pro
rata portion thereof, shall be suspended during the full period of any such prevention, but payment of monies which has accrued for payment prior to, or after such cause shall not be excused. 

13.15 Accounting Principles. Any reference in this Agreement to generally accepted accounting principles refers to generally accepted accounting
principles as approved from time to time by the Canadian Institute of Chartered Accountants or any successor institute. 
 13.16 Best of
Knowledge. “To the best of the knowledge” or “to the knowledge”, unless otherwise qualified hereunder means a statement of the declaring party’s knowledge of the actual facts or circumstances to which such phrase relates
without having made any inquiries or investigations in connection with such facts and circumstances. 
  

 20 

 13.17 Counterparts and Facsimile. This Agreement may be executed in counterparts and by facsimile
each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF,
MBI and UHN have executed this Agreement through their duly authorized representatives as of the Effective Date. 
  

									
	MED BIOGENE INC.	 		 	UNIVERSITY HEALTH NETWORK
					
	by:	 	/s/ ERINN B. BROSHKO	 		 	by:	 	/s/ CHRISTOPHER J. PAIGE
		 	Erinn B. Broshko	 		 		 	Christopher J. Paige, Ph.D.
		 	Chief Executive Officer	 		 		 	Vice President, Research

 We, the Principal Investigators,
have read the provisions of this Agreement and will use our best efforts as employees and/or staff members of UHN to direct the Additional Research Program in accordance with said provisions and as directed by UHN. 

 

					
	Principal Investigators	 		 	
			
	/s/ MING-SOUND TSAO	 		 	/s/ FRANCES A. SHEPHERD
	Ming-Sound Tsao, M.D.	 		 	Frances A. Shepherd, M.D.

  

 21 

 SCHEDULE A 

Additional Research Program 

The Additional Research Program will be conducted in respect of the Additional Licensed Technology described in the United States provisional patent
application “Prognostic and Predictive Gene Signature for Non-Small Cell Lung Cancer and Adjuvant Chemotherapy”, filed on May 14, 2008 under number 058187-0114 and the presentation, “A 15-gene expression signature prognostic for
survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients” presented by Dr. Ming-Sound Tsao at the American Society for Clinical Oncology 2008 Annual Meeting (J Clin Oncol 26: 2008 [May 20 suppl; abstr 7510]). Briefly,
gene expression profiling by Affymetrix whole genome microarrays was performed on RNA isolated from snap-frozen banked tumour tissues of 133 (62 on observation and 71 on chemotherapy) JBR.10 stage IB and II patients. The expression signature of a
minimal prognostic set of 15 genes separated the 62 observation patients into groups with high and low risk for death. This prognostic signature was validated in five independent public gene expression datasets of stage I-II patients. Chemotherapy
significantly reduced the risk of death in high-risk stage 1B and II patients; the benefit of chemotherapy was seen both in high-risk stage IB and stage II patients, but not in low-risk stage IB and II patients. The 15-gene signature is an
independent prognostic marker in early stage NSCLC for identifying more selectively than staging alone, patients who may benefit from adjuvant chemotherapy. 

The Additional Research Program will focus on advancing the development of a molecular assay based on the 15-gene signature that may be used in clinical
reference laboratories to predict prognosis and adjuvant chemotherapy benefit from tumour samples collected from patients diagnosed with stage I or II NSCLC. UHN believes that such a commercially available assay would provide to oncologists
additional and valuable patient information to assist in determining whether a patient should undergo adjuvant chemotherapy. 
 The Additional
Research Program will be conducted in a collaborative fashion by UHN and MBI as described below. It is anticipated that UHN and MBI will, in a timely manner, keep each other apprised of the research, analysis and results of the Additional Research
Program and provide the other party the opportunity to provide input and suggestions as to the research. Notwithstanding the foregoing, the parties acknowledge that UHN and MBI shall collaborate in determining the method of analysis of the Clinical
Data and shall also collaborate in interpreting the results of such analysis, provided that UHN shall maintain possession of the Clinical Data and do such work as necessary under the Additional Research Program to allow for it to remain
confidential. 
 MBI acknowledges the significant scientific and clinical expertise, experience and reputations of the UHN research team, and
UHN acknowledges MBI’s commercial experience. The parties intend upon leveraging the strengths of each party in order to complete in a timely manner the contemplated research for peer-reviewed publication and to advance such research to allow
for the commercialization of a prognostic test to change the standard of care of patients with early-stage NSCLC. 
 Summary of Research

 The Additional Research Program will be undertaken in three phases. All three phases will begin immediately and will be undertaken
concurrently, but continuation of the Additional Research Project is dependent upon a positive outcome of Phase 1 and continuation of Phase 3 is dependent upon a positive outcome in Phase 2. 

Phase 1 represents a large-scale microarray validation study of the 15-gene signature using snap-frozen samples. At the end of this phase, the 15-gene
signature will be evaluated to determine its clinical and commercial utility and relevance. 

  Phase 2 comprises the development of a set of 15 TaqMan probe-based assays, and controls, that together
comprise the 15-gene signature and the validation of this signature with an independent cohort of patient samples. 
 Phase 3 comprises a study,
using the 15 gene qPCR assay developed in Phase 2, to validate and optimize assay probe-primer sets for optimum performance with formalin-fixed, paraffin-embedded (“FFPE”) samples. It will also include the development of a sample
processing workflow and quality control metrics for harvesting RNA from such samples. Finally, this study will apply the FFPE-optimized 15-gene assay to examine the prognostic ability of the markers using FFPE samples corresponding to the same
cohort of patient samples from Phase 1. 
 [*] 

Phase 1: [*] 
 1. Phase 1 represents a
large-scale microarray validation study of the 15-gene signature using snap-frozen samples. 
 2. [*] 

3. [*] 
 4. [*] 

5. For greater certainty that this stage of the work will be successful, RNA from all of the samples described above shall be allocated to the analysis
and validation of the 15-gene signature first, then for studies for the validation of the 3 and 6 gene signatures under the Sponsored Research Agreement. 

Phase 2: [*] 
 6. While the results to
date in respect of the 15 gene signature on the Affymetrix microarray platform has been very impressive, ultimately, for cost, commercial and technical reasons, TaqMan qPCR is a preferable technology platform for the implementation and launch of the
15 gene signature as molecular prognostic test. 
   

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 2 

  7. Phase 2 comprises the development of a TaqMan qPCR probe-based assay panel in respect of the 15-gene
signature, and controls, for optimal use on snap-frozen and FFPE samples. Phase 2, however, will involve the analysis of RNA extracted from snap-frozen samples, whereas Phase 3 will involve the analysis of RNA extracted from FFPE samples.

 8. [*] 
 9. [*] 

10. [*] 
 11. [*] 

12. [*] 
 13. [*] 

14. [*] 
 Phase 3: [*] 

15. Phase 3 comprises a study to validate the use of the 15 gene qPCR assay developed in Phase 2 on FFPE tumour samples, including an examination of the
prognostic ability of the markers using FFPE samples. It will also include the development of a sample processing workflow and quality control metrics for harvesting RNA from such samples. 

16. [*] 
 17. [*] 

 

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 3 

 18. [*] 

19. [*] 
 20. [*] 

 

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 4 

 SCHEDULE B 

Budget 
  

																															
	 	 	 	 Justification
	 	[*]	 	 	[*]	 	 	[*]	 	 	[*]	 	 	[*]	 	 	 	 
	 Phase 1 - Microarray validation of 15-gene signature
	 				 		 				 				 				 				 				 			
	 [*]
	 				 		 				 				 				 				 				 			
	 [*]
	 	$	0	  	 		 				 				 				 				 				 			
	 [*]
	 	$	0	  	 		 				 				 				 				 				 			
	 [*]
	 	$	[	*] 	 	[*]	 				 				 				 				 				 			
	 [*]
	 				 		 				 				 				 				 				 			
	 [*]
	 	$	[	*] 	 	[*]	 				 				 				 				 				 			
	 Phase 1 subtotal
	 	$	[	*] 	 		 	 	[*]h	  	 	 	[*]h	  	 	 	[*]h	  	 	 	[*]h	  	 	 	[*]h	  	 			
		 				 		 	$	[	*] 	 	$	[	*] 	 	$	[	*] 	 	$	[	*] 	 	$	[	*] 	 	$	[	*] 
	 Phase 2 - qPCR development and validation (flash frozen)
	 				 		 				 				 				 				 				 			
	 [*]
	 	$	0	  	 		 				 				 				 				 				 			
	 [*]
	 	$	[	*] 	 	Christine Frantz	 				 				 				 				 				 			
	 [*]
	 	$	[	*] 	 		 				 				 				 				 				 			
	 [*]
	 	$	[	*] 	 	qPCR data analysis	 				 				 				 				 				 			
	 Phase 2 subtotal
	 	$	[	*] 	 		 				 				 				 				 				 			
		 				 		 	 	[*]h	  	 	 	[*]h	  	 	 	[*]h	  	 	 	[*]h	  	 	 	[*]h	  	 			
		 				 		 	$	[	*] 	 	$	[	*] 	 	$	[	*] 	 	$	[	*] 	 	$	[	*] 	 	$	[	*] 
	 Phase 3 - qPCR development and validation (FFPE)
	 				 		 				 				 				 				 				 			
	 [*]
	 	$	[	*] 	 	[*]	 				 				 				 				 				 			
	 [*]
	 	$	[	*] 	 	[*]	 				 				 				 				 				 			
	 Phase 3 subtotal
	 	$	[	*] 	 		 				 				 				 				 				 			
	 Miscl.
	 	$	[	*] 	 		 				 				 				 				 				 			
	Total	 	$	[	*] 	 		 	 	[*]h	  	 	 	[*]h	  	 	 	[*]h	  	 	 	[*]h	  	 	 	[*]h	  	 			
		 				 		 	$	[	*] 	 	$	[	*] 	 	$	[	*] 	 	$	[	*] 	 	$	[	*] 	 	$	[	*] 
	 Consulting/Success Fees
	 				 		 				 				 				 				 				 			
		 				 		 				 				 				 				 				 	$	[	*] 

  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 SCHEDULE C 

Additional Licensed Patents 
  

	1.	UHN Existing Patents and Patent Applications 

  

	 	(a)	Provisional Patent application entitled “Prognostic and Predictive Gene Signature for Non-Small Cell Lung Cancer and Adjuvant Chemotherapy”, M.-S. Tsao et al
(inventors); US Patent Appln. No. No. 61/071,728 (filed on May 14, 2008); and 

  

	 	(b)	New provisional patent application related to US Patent Appln. No. 61/071,728, expected to be filed in 2009, directed to capturing further embodiments of the
invention, for example, sub-sets of the 15-gene signature, and further embodiments encompassing the 15-gene signature (and sub-sets thereof) with additional genes that may be used in conjunction therewith, including that outlined in US Patent Appln.
No. 61/071,728. 

  

	2.	UHN Additional Research Program Patents 

UHN Additional Research Program Patents are to be added during the term of the Additional Sponsored Research Agreement. 

 

	3.	Joint Additional Research Program Patents 

Joint Additional Research Program Patents are to be added during the term of the Additional Sponsored Research Agreement. 

 

	4.	Continuations, Divisionals, Renewals, Extensions 

For greater certainty, the Additional Licensed Patents shall include: 
  

	 	(a)	any issued patent or patent application (including any provisional patent application or any patent application filed under any international Convention or Treaty)
described or listed in this Schedule A, 

  

	 	(b)	all continuations and continuations-in-part applications to the issued patent or patent application described in Paragraph 4(a) of this Schedule A (solely to the extent
such continuations-in-part applications contain subject matter on which claims issuing obtain the benefit of a priority date of any patent or patent application described in Paragraph 4(a) of this Schedule A), 

 

	 	(c)	all divisions, patents of addition, reissues, renewals and extensions of any of the patent, patent application, continuations and continuations-in-part applications set
out in Paragraphs 4(a) and 4(b) of this Schedule A, 

  

	 	(d)	all regular utility patent applications or patent applications filed under any international Convention or Treaty on the basis of any patent application(s) described or
listed in this Schedule A, and 

  

	 	(e)	all foreign counterparts of any of the foregoing (including, without limitation, European Supplementary Protection Certificates or its equivalent).

 SCHEDULE D 

Section 6.13 Disclosure 

None

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]